The objective of study GH101 is to take an integrative approach to the fields of pharmacogenomics, cancer genomics, mRNA microarrays and nutrigenomics. These disciplines have evolved from the original human genome project but have essentially remained discreet. The integration of these genetic disciplines into a computational model has the potential to increase diagnostic yield and provide a clearer genetic picture to determine actionable events to improve healthcare.
With the use of advanced technology, GH101 is designed to identify differentially expressed genes (DEGs) associated with development of chronic diseases such as CVD, ESRD, PTSD, and cancers.
The GH215 study is a diagnostic platform that utilizes ‘NuTec signatures’ created by the unbiased binding of molecules from patient urine specimens as a means of detecting diseases in people. This platform has been successfully tested in various clinical proof of concept studies involving urine specimens from donors with and without various cancers and infections.
Sign up to receive monthly updates on new product announcements, press releases, promotions, and more.
Speak to one of our representatives today to learn more about our CAP and CLIA-accredited laboratory.
Copyright © 2023 Genetics Institute of America. All Rights Reserved.
